Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
Arroyo
Vicente
V
Liver Unit, Institute of Digestive and Metabolic Diseases, Hospital Clinic, University of Barcelona, Barcelona, Spain. varroyo@clinic.ub.es
Terra
Carlos
C
Ginès
Pere
P
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D001201:Ascites / Q000150:complications; D002303:Cardiac Output, Low / Q000150:complications / Q000503:physiopathology; D005919:Glomerular Filtration Rate; D006530:Hepatorenal Syndrome / Q000145:classification / Q000150:complications / Q000503:physiopathology* / Q000628:therapy* / Q000652:urine; D006801:Humans; D007677:Kidney Function Tests; D008103:Liver Cirrhosis / Q000150:complications / Q000503:physiopathology*; D016031:Liver Transplantation; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D012079:Renal Circulation / Q000187:drug effects; D051437:Renal Insufficiency / Q000150:complications / Q000503:physiopathology*; D013152:Splanchnic Circulation / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents